NOSIUM (NOSIUM ) Q3 2025 earnings summary

Executive summary

• Q3 2025 marked by continued streamlining and financial strengthening, including the sale of Framgångsgården AB and a directed share issue to boost liquidity.

• Signed a binding agreement to acquire up to 89.9% of Medicortex Finland Oyj, transforming the business focus to advanced diagnostics.

Financial highlights

• Q3 2025 group net sales: 1,049 TKR (down 21% year-over-year); operating result: -1,138 TKR (improved from -1,623 TKR); net result attributable to parent shareholders: 13 TKR (from -5,296 TKR).

• Parent company Q3 net sales: 61 TKR (down 28%); operating result: -729 TKR (from -815 TKR); net result: 424 TKR (from -4,435 TKR).

• For Jan–Sep 2025, group net sales: 3,827 TKR (down 33%); operating result: -3,015 TKR (from -6,045 TKR); net result: -2,078 TKR (from -12,015 TKR).

• Cash flow from operations Q3: group -953 TKR (from -1,594 TKR); parent -723 TKR (from -270 TKR).

Outlook and guidance

• Completion of the Medicortex acquisition expected in H1 2026, with ongoing efforts to divest remaining holdings and finalize business streamlining.